Daisuke Kotani: SCRT vs LCRT in Rectal Cancer
Daisuke Kotani/X

Daisuke Kotani: SCRT vs LCRT in Rectal Cancer

Daisuke Kotani, GI Medical Oncologist, Chief Physician at the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, Japan, shared a post on X about a recent article by Lily V.S. Hillson et al, published in Clinical Cancer Research:

“Immunological Dynamics in Rectal Cancer: SCRT vs LCRT

  • Circulating lymphocytes: SCRT (less depletion) > LCRT
  • Immune cells in TME: SCRT (higher density of CD8+ & FOXP3+) > LCRT, no diff. in FOXP3/CD8 ratio

SCRT is potentially preferred backbone in combination with ICIs.”

Title: Differential Immunological Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer

Authors: Lily V.S. Hillson, Ross K. McMahon, Norman J. Galbraith, Ashley K. McCulloch, Chia Yew Kong, Walaiphorn Woraharn, Lydia Melissourgou-Syka, Kathryn A.F. Pennel, Jean A. Quinn, Leia Jones, Raheleh Amirkhah, Natalie Fisher, Noori Maka, Aula Ammar, Phimmada Hatthakarnkul, Liang Tang, Annabelle Smith, Simon Milling, Alec C. McDonald, Harikrishnan Nair, Paul G. Horgan, Colin W. Steele, Janet S. Graham, Philip D. Dunne, Joanne Edwards, Sean M. O’Cathail, Campbell S. Roxburgh

Read the Full Article on Clinical Cancer Research

Daisuke Kotani: SCRT vs LCRT in Rectal Cancer

More posts featuring Daisuke Kotani.